Fresenius SE Receivables 2016-2023 | FSNUY

Fresenius SE receivables for the quarter ending September 30, 2023 were $4.529B, a 44.8% decline year-over-year.

  • Fresenius SE receivables for 2022 were $7.549B, a 11.28% decline from 2021.
  • Fresenius SE receivables for 2021 were $8.509B, a 5.7% increase from 2020.
  • Fresenius SE receivables for 2020 were $8.05B, a 1.22% decline from 2019.

Fresenius SE Receivables 2016-2023 | FSNUY

  • Fresenius SE receivables for 2022 were $7.549B, a 11.28% decline from 2021.
  • Fresenius SE receivables for 2021 were $8.509B, a 5.7% increase from 2020.
  • Fresenius SE receivables for 2020 were $8.05B, a 1.22% decline from 2019.
Related Stocks
Company NameMarket
Cap
Quest Diagnostics (DGX)$17.3B
DaVita (DVA)$13.7B
Encompass Health (EHC)$9.3B
Chemed (CHE)$8.7B
Elanco Animal Health (ELAN)$7.2B
Option Care Health (OPCH)$5.3B
RadNet (RDNT)$5B
Amedisys (AMED)$3.2B
Astrana Health (ASTH)$2.8B
LifeStance Health (LFST)$2.6B
Addus HomeCare (ADUS)$2.4B
U.S Physical Therapy (USPH)$1.3B
Pennant (PNTG)$1.1B
Aveanna Healthcare Holdings (AVAH)$1B
Atai Life Sciences (ATAI)$208M
Daxor (DXR)$45M
ATI Physical Therapy (ATIP)$25M
MEDIROM Healthcare Technologies (MRM)$19M
Psychemedics (PMD)$14M
Ontrak (OTRK)$10M
Novo Integrated Sciences (NVOS)$6M
IMAC Holdings (BACK)$2M